Clinical Trials Browser

Phase 2/3 × INDUSTRY × AP 1903 reagent × Clear all

NCT03699475 2023-09-29

THRIVE

Phase 2/3 Terminated

1 enrolled 9 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute